| dc.description.abstract | Several plants have been used extensively for the treatment of diabetes and its related conditions throughout the world. Most plants contain a diverse range of phytochemicals and can often have anti-diabetic effects. Among the multitude of plants, Momordica charantia L. is a well-known plant, and it is cultivated as a medicinal vegetable for the management of diabetes in tropical and subtropical areas such as East Africa, Asia, South America, and the Caribbean. Various extracts and isolated compounds have been reported to have significant anticancer and antitumor activity, glucose reducing the effect and AMP-activated protein kinase activities. To further understand the role of compounds from this plant, the current thesis work describes the isolation, structure elucidation, and bioactivities of compounds from the bitter melon. In the first study, three cucurbitane-type triterpene aglycones such as four compounds were isolated from the EtOAc extract of bitter melon fruit. Charantoside XI is a novel cucurbitane-type triterpene containing a carboxylic acid from Momordica charantia. The isolated compounds were assessed for their anti-diabetic and antiinflammatory activities
In the second study, six triterpene glycosides such as momordicoside I, F1, K, F2, G, and Karaviloside XI, a new phenolic derivative 2-hydroxy-5-O-β-D-xylopyranosyl benzoic acid, benzoic acid, phenylalanine, and quercetin-7-O-β-glucopyranoside were isolated from the polar extracts of bitter melon and evaluated for in vitro and in silico anti diabetic and anti-inflammatory activities. | en |
